- Home
- RCUS vs AVDX Comparison
RCUS vs AVDX Comparison
Compare RCUS & AVDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- AVDX
- Stock Information
- Founded
- RCUS 2015
- AVDX 2000
- Country
- RCUS United States
- AVDX United States
- Employees
- RCUS N/A
- AVDX N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- AVDX EDP Services
- Sector
- RCUS Health Care
- AVDX Technology
- Exchange
- RCUS Nasdaq
- AVDX Nasdaq
- Market Cap
- RCUS 1.4B
- AVDX 1.6B
- IPO Year
- RCUS 2018
- AVDX 2021
- Fundamental
- Price
- RCUS $15.52
- AVDX $10.54
- Analyst Decision
- RCUS Buy
- AVDX Hold
- Analyst Count
- RCUS 12
- AVDX 15
- Target Price
- RCUS $34.50
- AVDX $11.70
- AVG Volume (30 Days)
- RCUS 755.7K
- AVDX 1.6M
- Earning Date
- RCUS 11-06-2024
- AVDX 11-06-2024
- Dividend Yield
- RCUS N/A
- AVDX N/A
- EPS Growth
- RCUS N/A
- AVDX N/A
- EPS
- RCUS N/A
- AVDX N/A
- Revenue
- RCUS $263,000,000.00
- AVDX $427,566,000.00
- Revenue This Year
- RCUS $127.13
- AVDX $17.55
- Revenue Next Year
- RCUS N/A
- AVDX $10.57
- P/E Ratio
- RCUS N/A
- AVDX N/A
- Revenue Growth
- RCUS 119.17
- AVDX 17.84
- 52 Week Low
- RCUS $13.52
- AVDX $7.38
- 52 Week High
- RCUS $20.31
- AVDX $13.56
- Technical
- Relative Strength Index (RSI)
- RCUS 44.11
- AVDX 46.09
- Support Level
- RCUS $14.78
- AVDX $10.54
- Resistance Level
- RCUS $18.07
- AVDX $11.37
- Average True Range (ATR)
- RCUS 0.96
- AVDX 0.33
- MACD
- RCUS -0.16
- AVDX -0.18
- Stochastic Oscillator
- RCUS 22.32
- AVDX 21.32
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About AVDX AvidXchange Holdings Inc.
AvidXchange Holdings Inc is a provider of AP automation software and payment solutions for middle-market businesses and their suppliers. It generates the majority of its sales from Payment revenue followed by Software revenue and Services revenue. The company generates revenue in the United States.